Objective: Demonstrate the involvement of our structurally targeted allosteric regulator Parkinson’s disease (PD) candidate, GT-02287, in decreasing the CBE-induced neurotoxic effect and in restoring lysosomal health in dopaminergic primary rat neurons and in CBE-treated mice.
Background: GBA1 encodes the lysosomal enzyme glucocerebrosidase (GCase), whose deficiency has been linked to increased alpha-synuclein pathology, as well as to lysosomal, mitochondrial and endoplasmic reticulum stress, key pathophysiological features in PD. Importantly, GBA1 mutations also increase the risk factor for sporadic PD.
Method: Gain Therapeutics applies its innovative proprietary drug discovery platform, Site-directed Enzyme Enhancement Therapy (SEE-Tx™), to the development of small-molecule structurally targeted allosteric regulators (STARs) that stabilize GCase avoiding its degradation whilst facilitating its maturation and trafficking to the lysosomes. GT-02287 is a small molecule identified by the SEE-Tx platform, that exhibits a good toxicology profile and enhances GCase activity and levels by promoting its stabilization.
CBE, a covalent inhibitor that reacts with the catalytic site of GBA and inactivates the enzyme, was used to cause a partial defect of GCase activity comparable to heterozygotes GBA-PD patients. CBE-based models represent an additional tool to study pathophysiological pathways in PD under GCase defect and are considered relevant for the development of treatments for the disease.
Results: We report in vitro and in vivo evidence showing pharmacological chaperone-mediated activity by our orally bioavailable and brain penetrant lead, GT-02287, in dopaminergic rat neurons injured with CBE and in chronically treated mice. This is shown as a counteracting effect of the CBE-induced neurotoxicity and as an improvement of the lysosomal health.
Conclusion: Enhancement of the lysosomal GCase activity by GT-02287 protects against key pathophysiological hallmarks of PD, including alpha-synuclein and lysosomal related pathology, ameliorating dopaminergic cells phenotype. Therefore, STARs therapy represents a novel pharmacological tool for the treatment of PD, warranting further development towards the clinic.
To cite this abstract in AMA style:B. Guzman, N. Perez, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, A. Henriques, L. Rouviere, R. Maj. GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/gt-02287-a-brain-penetrant-structurally-targeted-allosteric-regulator-for-glucocerebrosidase-show-evidence-of-pharmacological-efficacy-in-conduritol-%ce%b2-epoxide-cbe-models-of-parkinsons/. Accessed March 1, 2024.
« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/gt-02287-a-brain-penetrant-structurally-targeted-allosteric-regulator-for-glucocerebrosidase-show-evidence-of-pharmacological-efficacy-in-conduritol-%ce%b2-epoxide-cbe-models-of-parkinsons/